Skip to main content
Past Event

Understanding and Discussing the Implications of FDA’s Sentinel Initiative

On October 25, the Engelberg Center hosted and expert workshop, “Understanding and Discussing the Implications of FDA’s Sentinel Initiative,” which focused on issues of importance for medical product developers.

This meeting brought together representatives to discuss the role of FDA’s pilot program, Mini-Sentinel, within FDA’s broader array of tools to monitor medical product safety and to discuss mechanisms for how developers could support and engage with FDA on Sentinel-related activities.

Learn more about Expert Workshops>>



Sentinel's Progress: Past, Present, and Future

Mini Sentinel's Current Active Surveillance Capabilities


Rich Platt

Harvard Medical School and Harvard Pilgrim Health Care Institute

Stakeholder Roles in Sentinel


Rachel Sherman

Principal, Drug and Biological Drug Products - Greenleaf Health LLC

Proposed Role of Medical Product Developers in the Execution of Safety Surveillance Activities

Proposal for Medical Product Developers to Support Safety Science Methods Research and Development

Remarks from the Director of FDA's Center for Drug Evaluation and Research


Janet Woodcock

Director, Center for Drug Evaluation and Research - US Food and Drug Administration

Closing Remarks and Adjournment

More Information


Get a weekly events calendar from Brookings